Apithecary Pharma Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 23-10-2024
- Paid Up Capital ₹ 4.26 Cr
as on 23-10-2024
- Company Age 19 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 14.53 Cr
as on 23-10-2024
- Revenue 7.94%
(FY 2023)
- Profit 95.68%
(FY 2023)
- Ebitda 93.03%
(FY 2023)
- Net Worth -0.17%
(FY 2023)
- Total Assets -0.17%
(FY 2023)
About Apithecary Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 4.26 Cr.
The company has closed loans amounting to ₹14.53 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Munnamgi Reddy and Munnamgi Reddy serve as directors at the Company.
- CIN/LLPIN
U24239TG2005PTC047834
- Company No.
047834
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Oct 2005
- Date of AGM
20 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Apithecary Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Munnamgi Reddy  | Managing Director | 20-Oct-2005 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Munnamgi Reddy | Director | 15-Mar-2021 | Current |
Financial Performance of Apithecary Pharma.
Apithecary Pharma Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 7.94% increase. The company also saw a substantial improvement in profitability, with a 95.68% increase in profit. The company's net worth dipped by a decrease of 0.17%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Apithecary Pharma?
In 2023, Apithecary Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Nine Labs Private LimitedActive 16 years 9 monthsMunnamgi Reddy and Munnamgi Reddy are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Andhra Pradesh State Financial Corporation Creation Date: 20 Jul 2013 | ₹2.18 Cr | Satisfied |
Andhra Pradesh State Financial Corporation Creation Date: 20 Apr 2013 | ₹3.00 Cr | Satisfied |
Andhra Pradesh State Finacial Corporation Creation Date: 06 Oct 2009 | ₹2.16 Cr | Satisfied |
How Many Employees Work at Apithecary Pharma?
Unlock and access historical data on people associated with Apithecary Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Apithecary Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Apithecary Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
